

# Ayuda Investigador AECC 2026

## Adjudicaciones

<b>Dra. Natalia Martín</b> Centro de Investigación Cooperativa en Biociencias (CIC bioGUNE)	Paracrine and Autocrine Communication in Metastatic hormone-Naïve prostate cancer (PACMeN)
<b>Dr. Pedro Ortega</b> Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER)	Dissecting cancer cell vulnerabilities to the synergistic effects of ATR and PARP co- inhibition
<b>Dra. Teresa Lozano</b> Cancer Center Clínica Universidad de Navarra (CIMA-CCUN)	Improving CAR-T cell efficacy by targeting the tumor microenvironment
<b>Dr. Alberto Martín</b> Centro de Investigación del Cáncer (CSIC - Universidad de Salamanca)	Exploring novel therapeutic strategies to enhance the antitumor effect of oncogenic KRAS protein degradation in lung adenocarcinoma
<b>Dra. Cristina Oancea</b> Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS)	4D LET and dose verification in proton therapy for head and lung tumors using Spectro-tracking detectors and AI-based reconstruction
<b>Dra. Judit Liano</b> Vall d'Hebron Instituto de Oncología (VHIO)	Mapping the metabolic landscape of gastrointestinal stromal tumors for therapeutic intervention
<b>Dra. Aïda Falgàs</b> Instituto de Investigación contra la Leucemia Josep Carreras (IJC)	Engineered T cells secreting dual bispecific CD19xCD3 and CD22xCD3 T-cell engagers to prevent antigen-escape in B- cell malignancies
<b>Dr. Damià Romero</b> Instituto de Investigación Biomédica de Bellvitge (IDIBELL)	Dissecting hematopoietic-niche crosstalk to prevent leukemic transformation in GATA2 deficiency

**Dra. Amaya López**  
Cancer Center Clínica Universidad de  
Navarra (CIMA-CCUN)

Metabolic-epigenetic crosstalk in liver  
cancer: innovative therapeutics (MEC-LIC-  
IT)

## Suplentes

**Dr. Antonio Delgado**  
Centro Pfizer-Universidad de  
Granada-Junta de Andalucía de  
Genómica e Investigación  
Oncológica (GENYO)

INSIGHT-OC: cell intrinsic and spatial  
mechanisms of drug resistance identified  
for therapeutic intervention in Ovarian  
Carcinoma

**Dra. Sara Sánchez**  
Hospital Sant Joan de Dèu

Enhancer disruption: the new generation  
of epigenetic targeted therapy in Ewing  
Sarcoma

**Dr. Francesco Grussu**  
Vall d'Hebron Instituto de Oncología  
(VHIO)

Radiological-histopathological cancer  
digital twins for non-invasive tumour  
microenvironment characterisation

**Dra. Lucía Trilla**  
Instituto de investigación Biomédica  
Hospital Universitario La Paz  
(IdiPAZ)

Study of the role of tumour microbiota in  
response to immunotherapy using  
metagenomics and metaproteomics of  
paraffin samples

**Dra. Jenifer García**  
Instituto de Investigación Sanitaria  
de Santiago (IDIS)

BRIGHT (Breast cancer Glycoengineering  
& Targeted ALDH inhibition Therapy)

**Dr. Daniel Delgado**  
Instituto de Biomedicina de Sevilla  
(IBIS)

Basal hypoxia as a genetically-  
programmed driver of tumour Initiation